Test Price
2,800 AED✅ Home Collection Available
ACTA2 Gene Moyamoya Disease Type 5 Genetic Test – NGS Analysis in Dubai
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing (NGS) workflow.
Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across Dubai and the UAE.
Clinical Guidance: Post‑test telephone consultation with a consultant medical geneticist to review results and recommend family cascade screening.
Insurance: Direct billing verification via WhatsApp – send your policy details to +971 54 548 8731 for immediate eligibility confirmation.
Test Overview & Methodology
The ACTA2 gene NGS test delivers a definitive molecular diagnosis for Moyamoya disease type 5, a rare progressive cerebrovascular disorder characterised by stenosis of the internal carotid artery and compensatory collateral vessel formation. Whole‑gene sequencing identifies single‑nucleotide variants, small insertions and deletions, and copy number changes across the entire ACTA2 coding region. Early molecular confirmation enables timely intervention, informed family screening, and personalised treatment planning.
| Feature | ACTA2 NGS Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Methodology | Full‑gene next‑generation sequencing with high coverage and bioinformatics validation | Sanger sequencing limited to hot‑spot variants |
| Diagnostic Precision | 99.9% sensitivity for pathogenic and likely pathogenic mutations | ~85% – may miss rare or deep intronic alterations |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Price | 2,800 AED (pre‑test counselling included) | 2,500–3,200 AED (without integrated counselling) |
| Insurance Support | Direct billing verification via WhatsApp | Self‑claim only |
Physician Insight & Safety Protocols
"As a consultant medical geneticist, I recognise the profound impact a molecular diagnosis of Moyamoya disease type 5 can have on a patient and their family. The ACTA2 NGS test provides a robust foundation for early intervention and presymptomatic cascade screening. However, genetic results must always be interpreted in the context of a complete neurological evaluation, including cerebral angiography and family pedigree analysis. I urge every individual to engage in pre‑test counselling and maintain a close partnership with their specialist throughout the diagnostic journey."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA ID: 9294403
Medication & Clinical Advisory
Do not alter or discontinue any prescribed medication without prior approval from your treating physician. This genetic test is intended to inform long‑term risk management and family planning; it does not replace ongoing clinical monitoring or acute neurological care.
Safety & Exclusion Criteria
- Exclusion Criteria: Individuals under 18 years of age without court‑approved consent and documented pre‑test genetic counselling. Asymptomatic testing without a confirmed family history of ACTA2‑related disease is not recommended unless requested by a board‑certified neurologist or cardiologist.
- Emergency Red Flags: Sudden severe headache, seizure, unilateral vision loss, facial droop, or stroke‑like symptoms require immediate emergency department evaluation. This test is not designed for acute diagnosis and should never delay urgent neuroimaging or specialist referral.
Patient FAQ & Clinical Guidance
1. What is the purpose of the ACTA2 gene test for Moyamoya disease type 5?
Answer: The ACTA2 NGS test identifies pathogenic mutations responsible for Moyamoya disease type 5, enabling early stroke prevention, precise genetic counselling, and cascade screening of at‑risk relatives. The analysis covers the complete ACTA2 coding region, detecting single‑nucleotide variants, small insertions/deletions, and copy number variations. This comprehensive profile is essential for symptomatic individuals, those with a positive family history, and presymptomatic family members.
2. How is the sample collected and what is the turnaround time?
Answer: A peripheral blood sample is collected by our certified phlebotomist at your home or office (daily 8 AM – 11 PM) using temperature‑controlled cold‑chain equipment. Once received at our ISO‑accredited laboratory, DNA extraction, targeted enrichment, deep sequencing, and bioinformatic analysis are performed. A detailed clinical report and telephonic guidance from our consultant medical geneticist are delivered within 3 to 4 weeks of sample collection.
3. Is the test covered by health insurance in the UAE?
Answer: Yes – we offer direct billing verification via WhatsApp to confirm your policy eligibility and pre‑approval requirements. Our insurance liaison team communicates directly with your insurer to determine coverage and minimise out‑of‑pocket expenses. Send your insurance card and policy details to +971 54 548 8731 for an immediate eligibility check.
4. What pre‑test preparation is required?
Answer: A mandatory pre‑test genetic counselling session is required to construct a detailed three‑generation family pedigree, document any history of cerebrovascular events, and review the implications of possible results. No fasting or medication adjustments are needed before the blood draw. Your counsellor will ensure you understand the scope of the test, possible outcomes, and the importance of post‑test follow‑up.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
- Data Protection: All genetic and personal data are processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Testing protocols and patient consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring transparent risk communication and informed decision‑making.
- Laboratory Accreditation: DNA Labs UAE operates under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and is licensed by the Dubai Health Authority (DHA Facility License No. 1143).
Clinical & Logistical Metadata
| Test Name | ACTA2 Gene Moyamoya Disease Type 5 Genetic Test (NGS) |
| Price (AED) | 2,800 AED (includes pre‑test genetic counselling and telephonic post‑test guidance) |
| Turnaround Time | 3–4 weeks from sample receipt at laboratory |
| Sample Type / Matrix | Peripheral whole blood – VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection (daily 8 AM – 11 PM) |
| Methodology Used | Whole‑gene next‑generation sequencing (NGS) with high‑coverage bioinformatics analysis |
| ICD-10-CM Code | I67.5, Q28.8, Z15.89 |
| LOINC Code | 81765-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians